Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics is a San Diego biotechnology company developing a cell therapy for Duchenne muscular dystrophy. It last closed at $8.41 on Nov 17, up 1.33% on the day. CAPR last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 4 analysts is $20.38 (+142.3% from the last close), with a high of $25.00 and a low of $10.50. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CAPR, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print totaling $250K, the largest $250K.
Key Stats
Fiscal 2025Not reported for this period.
From CAPR's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 10).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on CAPR in the past 90 days. The average target is $20.38, with a high of $25.00 and a low of $10.50, compared with the last close of $8.41.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Roth Capital | Reiterated | Hold | $10.50 |
| Nov 11 | Jones Trading | Upgrade | Buy | $25 |
| Sep 14 | B. Riley Securities | Upgrade | Buy | $21 |
| Sep 1 | Piper Sandler | Upgrade | Buy | $2 → $25 |
| Aug 14 | Cantor Fitzgerald | Upgrade | Buy | $3.50 → $28 |
Technical Analysis
The stock is 6% above its 20 day and 4% above its 50 day average. It is 136% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the swing low (Sep 10) at $8.18, and the nearest resistance the Pivot at $8.53.
| RSI (14) | 50.65 | Middle of its range | Neutral |
| MACD | 0.47 | Above its signal line | Bullish |
| Stochastic | 53.0 | Middle of its range | Neutral |
| ADX (14) | 29.1 | Trending up | |
| Williams %R | -55.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 33.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +2.1% | Change over 10 sessions | Bullish |
| ATR (14) | $0.97 | Typical daily range, 11.5% of price |
| RSI (14) | 39.89 | Weak, oversold below 30 | Neutral |
| MACD | -3.49 | Above its signal line | Bullish |
| Stochastic | 66.5 | Middle of its range | Neutral |
| ADX (14) | 22.4 | Weak trend | |
| Williams %R | -50.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -19.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +0.5% | Change over 10 sessions | Bullish |
| ATR (14) | $2.78 | Typical daily range, 33.0% of price |
What happened before
See how CAPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CAPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.
Whale Options Flow
90DNo whale options trades in CAPR in the last 90 days.
Dark Pool
30DCAPR Institutional Ownership
Full report →- ●93 buying vs 86 selling
- ▲Held by funds +1.8 pts
- ▼Funds holding -12
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 158 | 170 | −7.1% |
| In funds' top 10 | 0 | 3 | −100.0% |
| Held by funds | 69.3% | 67.6% | +1.8 pts |
| New / increased | 35 / 58 | 26 / 71 | −4.1% |
| Reduced / sold out | 39 / 47 | 45 / 35 | +7.5% |
| Put/call ratio | 0.66 | 0.46 | +43.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAPR is in one of them and how their past CAPR trades turned out.
CAPR News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CAPR in an article yet. Here's the latest on the wider market.
CAPR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Roger MarshallR · KS | Sell | $1K – $15K | Jul 27, 2017 | Aug 6, 2018 | 375 d |
| Roger MarshallR · KS | Buy | $1K – $15K | Jul 27, 2017 | Aug 6, 2018 | 375 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company based in San Diego, California. It is developing Deramiocel, a cell therapy for Duchenne muscular dystrophy, a rare genetic disease that causes progressive muscle loss and weakness. The company is also studying a platform built on exosomes, which are small vesicles released by cells, for other possible diseases. It has no approved products yet, and its target patients are people living with this condition.
- Headquarters
- San Diego, CA



